Tell Every Amazing Lady® has funded research at some of the country’s most prestigious hospitals and institutions. We are proud to announce funding for the study “Characterizing CA 125-antibody interactions using proteomics,” led by Professor Rebecca Whelan at the University of Notre Dame.
Professor Whelan proposes to explain what exactly is causing the most widely used blood test for ovarian cancer to fail for early detection. The commonly used test detects the cancer biomarker CA125 at specific points of contact (“epitopes”) that are currently unknown. They will characterize the epitopes on CA125 at which affinity reagents (“antibodies”) recognize and bind to CA125, the interaction that is the basis of the blood test. Identifying the epitopes of CA125 that are recognized in the existing blood test is a necessary step to developing the next generation test, one that displays more reliable recognition of CA125 and therefore enables ovarian cancer to be detected in an earlier, more treatable stage. Funds for this study were made possible by donations to the T.E.A.L.® Jane Fund.
